Chemomab Therapeutics (CMMB) Receivables - Other (2017 - 2022)

Chemomab Therapeutics (CMMB) posted Receivables - Other of $7000.0 for Q2 2022, down 66.67% on a QoQ basis from $21000.0 in Q4 2018.

Chemomab Therapeutics (CMMB) Receivables - Other (2017 - 2022) Analysis & Trends

Chemomab Therapeutics' Receivables - Other history runs 3 years deep, the most recent figure standing at $7000.0 for Q2 2022.

Quarterly Receivables - Other changed N/A year-over-year to $7000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $7000.0 (changed N/A YoY) and the FY2018 annual result came in at $21000.0, up 40.0% from the prior year.
Receivables - Other was $7000.0 for Q2 2022 at Chemomab Therapeutics, down from $21000.0 in the prior quarter.
Across five years, Receivables - Other topped out at $21000.0 in Q4 2018 and bottomed at $7000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Chemomab Therapeutics	124.14 Mn	113.77 Mn	-

Download Data